Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

DxS’s TheraScreen: K-RAS Mutation Kit Receives Canadian Approval For Use With Amgen’s Vectibix

DxS has had its TheraScreen: K-RAS Mutation Kit granted a licence by the regulatory body Health Canada for use as a diagnostic for anti-EGFR therapies and as the companion diagnostic for Amgen’s colorectal cancer therapy, Vectibix (panitumumab).

The availability of the TheraScreen: K-RAS Mutation Kit will allow colorectal cancer patients in Canada to be screened using the DxS diagnostic to assess their suitability for treatment with Vectibix. Studies have shown that patients with the non-mutated K-RAS gene may respond to treatment with Vectibix.

Dr. Kenneth Pritzker, Mount Sinai Services, Toronto, one of the leading centres carrying out K-RAS testing in Canada said This is extremely good news that we have a registered method for K-RAS testing. The DxS K-RAS test is simple to use, highly sensitive and is the companion diagnostic test of choice for assessing a patient’s response to Vectibix.

The approval of the TheraScreen: K-RAS Mutation Kit is a step forward in making personalised medicine more readily available to physicians and patients in Canada. The future of cancer treatment will be guided by the use of technological advances such as these, which enable physicians to better manage a patient’s disease or predisposition towards a disease. Physicians can choose a treatment approach that is likely to work best in the context of a patient’s genetic and environmental profile.